Dallas-based biotechnology company specializing in gene therapies, Nanoscope Therapeutics, has named Indian-American surgeon Sunil Gupta to its board of directors.
A leading retinal surgeon and medical entrepreneur, Gupta is the founder of Retina Specialty Institute (RSI) and Intelligent Retinal Imaging Systems (IRIS). He is known for his expertise in drug development and medical devices, from clinical trials to commercialization.
Gupta has led innovations in retinal care and telemedicine for diagnosing eye diseases. His telemedicine platform, IRIS, is designed to prevent blindness globally by enabling primary care settings to detect retinal conditions early. He was also the founder and chief medical officer of USRetina, one of the largest retina physician associations in the United States, which recently sold to McKesson.
“Nanoscope has assembled a world-class team of scientists, physicians and business leaders, and I am excited to contribute,” said Gupta on his appointment.
“Gupta possesses an extraordinary combination of medical and entrepreneurial expertise around the treatment of inherited retinal diseases and dry age-related macular degeneration,” said Nanoscope CEO Sulagna Bhattacharya. “He will be an invaluable member of Nanoscope’s board as we advance towards commercialization of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and dry-AMD.”
Chairman of the board Glenn Sblendorio welcomed Gupta, citing his strategic insight as essential to advancing Nanoscope’s mission. “With an enhanced regulatory pathway, we look forward to utilizing his strategic expertise as well as his network with the retinal community.”
Gupta’s medical background includes a degree from the University of Cincinnati College of Medicine and specialized training in vitreoretinal surgery.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login